From health concerns to funding, there’s no shortage of obstacles preventing humans from traveling beyond our solar system. But the main obstacle is propulsion: Our spacecraft…
Google AI announced the launch of the Google Research YouTube channel today. The channel is set to focus on a wide range of subjects like AI/ML, robotics, theory and algorithms, quantum computing, health and bioscience.
This new invention is highly scalable since its raw materials are commercially available and easy to access.
A team of researchers from the National University of Singapore’s (NUS) College of Design and Engineering (CDE) has developed a self-charging electricity generation (MEG) device that generates electricity from air moisture, according to a press release by the institution.
Imagine being able to generate electricity by harnessing moisture in the air around you with just everyday items like sea salt and a piece of fabric, or even powering everyday electronics with a non-toxic battery that is as thin as paper. A team of researchers from the National University of Singapore’s (NUS) College of Design and Engineering (CDE) has developed a new moisture-driven electricity generation (MEG) device made of a thin layer of fabric — about 0.3 millimetres (mm) in thickness — sea salt, carbon ink, and a special water-absorbing gel.
Imagine being able to generate electricity by harnessing moisture in the air around you with just everyday items like sea salt and a piece of fabric, or even powering everyday electronics with a non-toxic battery that is as thin as paper. A team of researchers from the National University of Singapore’s (NUS) College of Design and Engineering (CDE) has developed a new moisture-driven electricity generation (MEG) device made of a thin layer of fabric—about 0.3 millimeters (mm) in thickness—sea salt, carbon ink, and a special water-absorbing gel.
The concept of MEG devices is built upon the ability of different materials to generate electricity from the interaction with moisture in the air. This area has been receiving growing interest due to its potential for a wide range of real-world applications, including self-powered devices such as wearable electronics like health monitors, electronic skin sensors, and information storage devices.
Continue reading “Self-charging, ultra-thin device that generates electricity from air moisture” »
In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder (ADHD) may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases (LBD), by up to five-fold. Most of these studies have used data linked to health records in large population registers and include impressive sample sizes and adequate follow-up periods. We identify a number of methodological limitations as well, including potential diagnostic inaccuracies arising from the use of electronic health records, biases in the measurement of ADHD status and symptoms, and concerns surrounding the representativeness of ADHD and LBD cohorts. Consequently, previously reported risk associations may have been underestimated due to the high likelihood of potentially missed ADHD cases in groups used as “controls”, or alternatively previous estimates may be inflated due to the inclusion of confounding comorbidities or non-ADHD cases within “exposed” groups that may have better accounted for dementia risk. Prospective longitudinal studies involving well-characterized cases and controls are recommended to provide some reassurance about the validity of neurodegenerative risk estimates in ADHD.
Attention-deficit hyperactivity disorder (ADHD) is a psychiatric disorder beginning in childhood that is characterized by core symptoms of inattention, impulsivity, and hyperactivity (Biederman and Faraone, 2005; American Psychiatric Association, 2013; Faraone et al., 2015). Diagnostic criteria require symptoms to present in early childhood, before age 12, and cause impairment in daily activities in more than one setting (e.g., home, school, social environment, and/or interpersonal relationships; American Psychiatric Association, 2013). Although it is largely considered a childhood disorder, 40–60% of cases of ADHD persist into adulthood (Culpepper and Mattingly, 2010; Michielsen et al., 2012; Volkow and Swanson, 2013; Asherson et al., 2016), and the overall prevalence of adult ADHD ranges from 2 to 4% (Kieling and Rohde, 2012; Fayyad et al., 2017).
ADHD may persist into later life as well. Roughly 3% of adults over age 50 suffer from significant symptoms of attention-deficit/hyperactivity disorder (ADHD; Michielsen et al., 2012; Kooij et al., 2016), often presenting as executive dysfunction (e.g., absent-mindedness) and memory impairments (e.g., forgetfulness or difficulty learning new things; Rosler et al., 2010; Thorell et al., 2017; Callahan et al., 2021). These symptoms overlap with those of early neurodegenerative disease (Ivanchak et al., 2012; Pollack, 2012; Goodman et al., 2016; Callahan et al., 2017), and it is currently unclear whether ADHD is associated with an increased neurodegenerative risk, or if it is being misdiagnosed due to symptom overlap (Callahan et al., 2017). Clarifying this issue is crucial to reduce dementia misdiagnoses, and to guide treatment, which will differ depending on whether the disease course is assumed to be neurodegenerative or not.
A team of researchers in the Faculty of Engineering of The University of Hong Kong (HKU) has developed a coin-sized system that can read weak electrochemical signals and can be used for personalized health monitoring and the measurement of such conditions as diabetes, cardiovascular diseases and mental health. The discovery was featured on the cover of Analytical Chemistry.
The PERfECT System—an acronym for Personalized Electronic Reader for Electrochemical Transistors—is the world’s smallest system of its kind, measuring 1.5 cm x 1.5 cm x 0.2 cm and weighing only 0.4 gram. It is easily wearable, for instance integrated with a smartwatch or as a patch, to allow for continuous monitoring of biosignals such as glucose levels and antibody concentrations in blood and even sweat.
Continue reading “Coin-sized wearable biosensing platform for digital health” »
Researchers at Aalto University have developed a bio-based adhesive that can replace formaldehyde-containing adhesives in wood construction. The main raw material in the new adhesive is lignin, a structural component of wood and a by-product of the pulp industry that is usually burned after wood is processed. As an alternative to formaldehyde, lignin offers a healthier and more carbon-friendly way to use wood in construction.
The carbon footprint of timber construction is significantly lower than concrete construction, and timber construction has often been viewed as better for the health of human occupants as well. However, wood panels still use adhesives made from fossil raw materials. They contain formaldehyde, which can be harmful to health, especially for those working in the adhesive manufacturing process. People living in or visiting buildings can also be exposed to toxic formaldehyde from wood panels.
Lignin, on the other hand, comes from wood itself. It binds cellulose and hemicellulose together and gives wood its tough, strong structure. Lignin accounts for about a quarter of the weight of wood and is produced in huge quantities in the pulp and bioprocessing industry. Only two to five percent of the lignin produced is used, and the rest is burned in factories for energy.
Agility Robotics recently raised $150 million USD in part from Amazon to further develop its humanoid robot called “Digit” for logistics automation. New wearable, bendable, stretchable neuromorphic AI chip monitors health in real time. New machine learning model from MIT does college level math at a human level.
AI News Timestamps:
0:00 Humanoid Robot Worker For Amazon Automation.
3:00 New Wearable AI Chip.
5:08 New Machine Learning Math Model.
An Israeli company has launched a clinical trial to determine if its innovative microbiome-based therapeutic could increase the responsiveness of some cancer patients to immunotherapy.
The microbiome is gut bacteria – trillions of microorganisms that live in the intestinal tract and play a role in digestion, immunity and many other aspects of health.
Rehovot-based Biomica, a subsidiary of Evogene, dosed its first patients in a Phase I clinical trial at Rambam Health Care Campus last month with a new drug – BMC128 – that is expected to help patients who do not respond to immunotherapy. Specifically, the company hopes the trial will demonstrate the safety, tolerability and preliminary clinical effectiveness of its BMC128 microbiome-based immuno-oncology drug candidate in combination with immune checkpoint inhibitor (ICI) immunotherapy.
Comotion_design/iStock.
The U.S. Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative is a collaboration among the National Institutes of Health, Defense Advanced Research Projects Agency, National Science Foundation, Food and Drug Administration, Intelligence Advanced Research Projects Activity, and others. Since its inception in 2013, its goal has been to develop and use new technologies to examine how each neuron and neural circuit come together to “record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought.”
